€5.05
Your prediction
Amneal Pharmaceuticals Inc Stock
Pros and Cons of Amneal Pharmaceuticals Inc in the next few years
Pros
Cons
Performance of Amneal Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals Inc | -0.970% | - | - | - | - | - | - |
| Avid Bioservices Inc | -4.690% | -4.688% | -4.688% | -64.535% | 0.000% | -61.635% | 60.126% |
| Rockwell Medical Inc. | -3.210% | -8.083% | 5.199% | -29.436% | -22.783% | -83.573% | -96.962% |
| Gritstone Oncology Inc | -5.220% | -12.658% | -72.289% | -71.310% | -62.863% | -90.561% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Amneal Pharmaceuticals (AMRX) provide some interesting insights into the company's performance and position within the pharmaceutical industry. At first glance, AMRX's financials exhibit a mix of both positive and negative factors, indicating that a more in-depth analysis is required to form a comprehensive understanding of the company's financial health. In the following sections, the pros and cons of AMRX's financials will be examined, emphasizing the different aspects of the balance sheets, cash flow statements, and income statements.
Stable Revenue Growth: Over the last few years, AMRX has exhibited an upward trend in its revenues, increasing from $1.99 billion in 2020 to $2.21 billion in 2022. This increment reflects a capacity to grow despite the various challenges in the pharmaceutical industry and indicates a robust product portfolio and market presence.
Increasing Gross Profit: The company's gross profit has risen from $628 million in 2020 to $784 million in 2022, reflecting an improved ability to generate profits from its core operations.
